Organoid Modeling of the Tumor Immune Microenvironment

Cell

Volumn 175, Issue 7, 2018, Pages 1972-1988.e16

  Neal, James T ^a   Li, Xingnan ^a   Zhu, Junjie ^b   Giangarra, Valeria ^c   Grzeskowiak, Caitlin L ^a   Ju, Jihang ^a   Liu, Iris H ^a   Chiou, Shin Heng ^a   Salahudeen, Ameen A ^a   Smith, Amber R ^a   Deutsch, Brian C ^a   Liao, Lillian ^a   Zemek, Allison J ^a   Zhao, Fan ^a   Karlsson, Kasper ^a   Schultz, Liora M ^a   Metzner, Thomas J ^a   Nadauld, Lincoln D ^a   Tseng, Yuen Yi ^e   Alkhairy, Sahar ^e   Oh, Coyin ^e   Keskula, Paula ^e   Mendoza Villanueva, Daniel ^f   De La Vega, Francisco M ^f   Kunz, Pamela L ^a   Liao, Joseph C ^a   Leppert, John T ^a   Sunwoo, John B ^a   Sabatti, Chiara ^a,d   Boehm, Jesse S ^e   Hahn, William C ^e,g   Zheng, Grace X Y ^c   Davis, Mark M ^a,d   Kuo, Calvin J ^a   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford University   (United States)

^c 10x Genomics ^*  (United States)

^d STANFORD UNIVERSITY   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f TOMA Biosciences Inc   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

cancer; checkpoint inhibitor; immunotherapy; organoid; PD 1; PDO; single cell RNA seq; T cell receptor; TCR; tumor infiltrating lymphocyte

Indexed keywords

CHECKPOINT KINASE INHIBITOR; IMMUNE CHECKPOINT BLOCKADE; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; TUMOR PROTEIN;

AIR; AIR LIQUID SURFACE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIUM; GENE EXPRESSION; GENETICS; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; INFANT; LIQUID; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOLOGY; ORGANOID; PATIENT DERIVED ORGANOID; PRIORITY JOURNAL; RENAL CELL CARCINOMA; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNE MICROENVIRONMENT; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; COCULTURE; EXPERIMENTAL NEOPLASM; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; MALE; PATHOLOGY;

ANIMALS; B7-H1 ANTIGEN; COCULTURE TECHNIQUES; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; MODELS, IMMUNOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; ORGANOIDS; RECEPTORS, ANTIGEN, T-CELL; TUMOR MICROENVIRONMENT;

EID: 85057760528     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.11.021     Document Type: Article

References (59)

1. Anagnostou, V., Smith, K.N., Forde, P.M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 7 (2017), 264–276.
2. Azizi, E., Carr, A.J., Plitas, G., Cornish, A.E., Konopacki, C., Prabhakaran, S., Nainys, J., Wu, K., Kiseliovas, V., Setty, M., et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174 (2018), 1293–1308.
3. Bailey, P., Chang, D.K., Nones, K., Johns, A.L., Patch, A.M., Gingras, M.C., Miller, D.K., Christ, A.N., Bruxner, T.J., Quinn, M.C., et al., Australian Pancreatic Cancer Genome Initiative. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531 (2016), 47–52.
4. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehár, J., Kryukov, G.V., Sonkin, D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (2012), 603–607.
5. Boj, S.F., Hwang, C.I., Baker, L.A., Chio, I.I., Engle, D.D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M.S., et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160 (2015), 324–338.
6. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 1627–1639.
7. Brahmer, J., Reckamp, K.L., Baas, P., Crinò L., Eberhardt, W.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
8. Cancer Genome Atlas, N., Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
9. Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Caliò A., Cuppone, F., Sperduti, I., Giannarelli, D., Chilosi, M., et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS ONE, 10, 2015, e0130142.
10. Chen, J., Lau, B.T., Andor, N., Grimes, S.M., Handy, C., Wood-Bouwens, C., Ji, H.P., Single-cell transcriptome analysis identifies distinct cell types and intercellular niche signaling in a primary gastric organoid model. bioRxiv, 2018, 10.1101/190132.
11. Chevrier, S., Levine, J.H., Zanotelli, V.R.T., Silina, K., Schulz, D., Bacac, M., Ries, C.H., Ailles, L., Jewett, M.A.S., Moch, H., et al. An immune atlas of clear cell renal cell carcinoma. Cell 169 (2017), 736–749.
12. Cibulskis, K., Lawrence, M.S., Carter, S.L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E.S., Getz, G., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31 (2013), 213–219.
13. Croce, C.M., Isobe, M., Palumbo, A., Puck, J., Ming, J., Tweardy, D., Erikson, J., Davis, M., Rovera, G., Gene for alpha-chain of human T-cell receptor: location on chromosome 14 region involved in T-cell neoplasms. Science 227 (1985), 1044–1047.
14. Deng, J., Wang, E.S., Jenkins, R.W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A.R., et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 8 (2018), 216–233.
15. Dijkstra, K.K., Cattaneo, C.M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L.F., Slagter, M., van der Velden, D.L., Kaing, S., Kelderman, S., et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174 (2018), 1586–1598.
16. DiMarco, R.L., Su, J., Yan, K.S., Dewi, R., Kuo, C.J., Heilshorn, S.C., Engineering of three-dimensional microenvironments to promote contractile behavior in primary intestinal organoids. Integr. Biol. 6 (2014), 127–142.
17. Feder-Mengus, C., Ghosh, S., Reschner, A., Martin, I., Spagnoli, G.C., New dimensions in tumor immunology: what does 3D culture reveal?. Trends Mol. Med. 14 (2008), 333–340.
18. Feldman, S.A., Assadipour, Y., Kriley, I., Goff, S.L., Rosenberg, S.A., Adoptive cell therapy–tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors. Semin. Oncol. 42 (2015), 626–639.
19. Finnberg, N.K., Gokare, P., Lev, A., Grivennikov, S.I., MacFarlane, A.W. 4th, Campbell, K.S., Winters, R.M., Kaputa, K., Farma, J.M., Abbas, A.E., et al. Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures. Oncotarget 8 (2017), 66747–66757.
20. Forget, M.A., Tavera, R.J., Haymaker, C., Ramachandran, R., Malu, S., Zhang, M., Wardell, S., Fulbright, O.J., Toth, C.L., Gonzalez, A.M., et al. A novel method to generate and expand clinical-grade, genetically modified, tumor-infiltrating lymphocytes. Front. Immunol., 8, 2017, 908.
21. Fujii, M., Shimokawa, M., Date, S., Takano, A., Matano, M., Nanki, K., Ohta, Y., Toshimitsu, K., Nakazato, Y., Kawasaki, K., et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell 18 (2016), 827–838.
22. Gandini, S., Massi, D., Mandalà M., PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 100 (2016), 88–98.
23. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al., KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 2018–2028.
24. Gordon, S.R., Maute, R.L., Dulken, B.W., Hutter, G., George, B.M., McCracken, M.N., Gupta, R., Tsai, J.M., Sinha, R., Corey, D., et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545 (2017), 495–499.
25. Han, A., Glanville, J., Hansmann, L., Davis, M.M., Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat. Biotechnol. 32 (2014), 684–692.
26. Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
27. Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Pérez-Gracia, J.L., Han, J.Y., Molina, J., Kim, J.H., Arvis, C.D., Ahn, M.J., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
28. Hirt, C., Papadimitropoulos, A., Mele, V., Muraro, M.G., Mengus, C., Iezzi, G., Terracciano, L., Martin, I., Spagnoli, G.C., “In vitro” 3D models of tumor-immune system interaction. Adv. Drug Deliv. Rev. 79-80 (2014), 145–154.
29. Huang, A.C., Postow, M.A., Orlowski, R.J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J.R., Wenz, B., et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545 (2017), 60–65.
30. Jenkins, R.W., Aref, A.R., Lizotte, P.H., Ivanova, E., Stinson, S., Zhou, C.W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 8 (2018), 196–215.
31. Junttila, M.R., de Sauvage, F.J., Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501 (2013), 346–354.
32. Kamphorst, A.O., Pillai, R.N., Yang, S., Nasti, T.H., Akondy, R.S., Wieland, A., Sica, G.L., Yu, K., Koenig, L., Patel, N.T., et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl. Acad. Sci. USA 114 (2017), 4993–4998.
33. Klemm, F., Joyce, J.A., Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 25 (2015), 198–213.
34. Krieg, C., Nowicka, M., Guglietta, S., Schindler, S., Hartmann, F.J., Weber, L.M., Dummer, R., Robinson, M.D., Levesque, M.P., Becher, B., High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat. Med. 24 (2018), 144–153.
35. Lavin, Y., Kobayashi, S., Leader, A., Amir, E.D., Elefant, N., Bigenwald, C., Remark, R., Sweeney, R., Becker, C.D., Levine, J.H., et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169 (2017), 750–765.
36. Li, X., Nadauld, L., Ootani, A., Corney, D.C., Pai, R.K., Gevaert, O., Cantrell, M.A., Rack, P.G., Neal, J.T., Chan, C.W., et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat. Med. 20 (2014), 769–777.
37. Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., Tykodi, S.S., Sosman, J.A., Procopio, G., Plimack, E.R., et al., CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373 (2015), 1803–1813.
38. Neal, J.T., Kuo, C.J., Organoids as models for neoplastic transformation. Annu. Rev. Pathol. 11 (2016), 199–220.
39. Ootani, A., Li, X., Sangiorgi, E., Ho, Q.T., Ueno, H., Toda, S., Sugihara, H., Fujimoto, K., Weissman, I.L., Capecchi, M.R., Kuo, C.J., Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nat. Med. 15 (2009), 701–706.
40. Palucka, A.K., Coussens, L.M., The basis of oncoimmunology. Cell 164 (2016), 1233–1247.
41. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
42. Picelli, S., Faridani, O.R., Björklund, A.K., Winberg, G., Sagasser, S., Sandberg, R., Full-length RNA-seq from single cells using Smart-seq2. Nat. Protoc. 9 (2014), 171–181.
43. Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F.S., Schachter, J., Pavlick, A.C., Lewis, K.D., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16 (2015), 908–918.
44. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
45. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372 (2015), 320–330.
46. Satija, R., Farrell, J.A., Gennert, D., Schier, A.F., Regev, A., Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33 (2015), 495–502.
47. Sato, T., Stange, D.E., Ferrante, M., Vries, R.G., Van Es, J.H., Van den Brink, S., Van Houdt, W.J., Pronk, A., Van Gorp, J., Siersema, P.D., Clevers, H., Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141 (2011), 1762–1772.
48. Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M., Benyamin, F.W., Lei, Y.M., Jabri, B., Alegre, M.L., et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350 (2015), 1084–1089.
49. Spence, J.R., Mayhew, C.N., Rankin, S.A., Kuhar, M.F., Vallance, J.E., Tolle, K., Hoskins, E.E., Kalinichenko, V.V., Wells, S.I., Zorn, A.M., et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 470 (2011), 105–109.
50. Spitzer, M.H., Carmi, Y., Reticker-Flynn, N.E., Kwek, S.S., Madhireddy, D., Martins, M.M., Gherardini, P.F., Prestwood, T.R., Chabon, J., Bendall, S.C., et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168 (2017), 487–502.
51. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
52. Topalian, S.L., Taube, J.M., Anders, R.A., Pardoll, D.M., Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16 (2016), 275–287.
53. Tran, E., Robbins, P.F., Lu, Y.C., Prickett, T.D., Gartner, J.J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E.M., et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375 (2016), 2255–2262.
54. van de Wetering, M., Francies, H.E., Francis, J.M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161 (2015), 933–945.
55. Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359 (2018), 920–926.
56. Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N.I., Miller, W.H. Jr., Lao, C.D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16 (2015), 375–384.
57. Wei, S.C., Levine, J.H., Cogdill, A.P., Zhao, Y., Anang, N.A.S., Andrews, M.C., Sharma, P., Wang, J., Wargo, J.A., Pe'er, D., Allison, J.P., Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170 (2017), 1120–1133.
58. + intestinal stem-cell self-renewal. Nature 545 (2017), 238–242.
59. Zheng, G.X., Terry, J.M., Belgrader, P., Ryvkin, P., Bent, Z.W., Wilson, R., Ziraldo, S.B., Wheeler, T.D., McDermott, G.P., Zhu, J., et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun., 8, 2017, 14049.